ArticleCureus2022
Positive Antinuclear Antibody and Blaschkoid Lichen Planus Pigmentosus.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichen planus pigmentosus is a rare variant of lichen planus. It is an acquired pigmentary disorder of unknown etiology. It is characterized by dark brown and slate gray macules and patches. The nails, scalp, and oral mucosa are usually spared, unlike lichen planus. Lichen planus pigmentosus commonly involves the head and neck region as well as intertriginous areas such as the axillae, inframammary and inguinal regions. It can be associated with autoimmune diseases, endocrinopathies, and other variants of lichen planus such as fibrosing alopecia of the scalp. Variable clinical patterns of lichen planus pigmentosus including zosteriform, linear, and segmental had been published. Histopathologically, it is characterized by hyperkeratosis of the epidermis, hypergranulosis, variable degrees of lichenoid infiltration depending on the age of the lesion, and prominent melanin incontinence. Recent updates on erythema dyschromicum perstans that were considered similar to lichen planus pigmentosus, concluded that they could be differentiated on clinical bases as well as histopathology. Epidermal hyperkeratosis, hypergranulosis, apoptotic cells, lichenoid dermatitis, periappendageal infiltrate, and fibrosis with marked superficial dermal melanin incontinence aid to differentiate lichen planus pigmentosus from erythema dyschromicum perstans. During embryogenesis, cells migrate and follow developmental lines named after Blaschko, a German dermatologist, who first noted them. Blaschko's lines (BL), do not follow neural, vascular, or lymphatic pathways. They appear as V-shaped on the back, S-shaped on the abdomen, and linearly on limbs. We report a case of lichen planus pigmentosus over BL that is a rare presentation of the disease and associated positive antinuclear antibody (ANA) without overt manifestations of any connective tissue disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.